New antibody trial hopes to tame rheumatoid arthritis
NCT ID NCT07347860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called A-319 in 12 people with active rheumatoid arthritis who haven't responded well to other treatments. The main goal is to check if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and whether it triggers an immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Union Hospital
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?
- Can less be more? trial tests cutting RA medication doses
- Can a new pill tame rheumatoid arthritis when standard drugs fail?
- Can two common drugs tame rheumatoid arthritis?